Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and
idarubicin given in combination to newly diagnosed AML patients >60 years or relapsed AML
patients.
Another purpose of this study is to determine the dose limiting toxicities associated with
bortezomib in combination with idarubicin in newly diagnosed AML patients >60 years or
relapsed AML patients.